Comparison of Tamsulosin and Tadalafil effects in LUTS treatment considering patients’ atherosclerosis risk level
Open Access
- 9 July 2022
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Medicine & Surgery
- Vol. 80, 104137
- https://doi.org/10.1016/j.amsu.2022.104137
Abstract
To date, no study evaluates the effect of atherosclerosis risk level on the efficacy of BPH drug therapies. Therefore, the present study aimed to assess the effect of atherosclerosis risk levels on the effectiveness of Tamsulosin and Tadalafil in LUTS treatment. The present study was a randomized clinical trial that assessed men with LUTS symptoms (at least six months). The inclusion criteria were being older than 50 years, international prostate symptom score (IPSS) ≥ 13, and maximum urinary flow rate (Qmax) between 4 and 15 ml/s. Framingham Risk Score was used to measure atherosclerosis risk. The patients were classified into four groups, including group 1: Patients with low risk and treated with Tamsulosin (0.4 mg/day), group 2: Patients with low risk and treated with Tadalafil (5 mg/day), group 3: Patients with high risk and treated with Tamsulosin (0.4 mg/day), group 4: Patients with high risk and treated with Tadalafil (5 mg/day). The study included 44 and 38 patients receiving Tamsulosin and Tadalafil, respectively. The means (SD) of the baseline age for the Tamsulosin and Tadalafil groups were equal to 60.6 (6.8) and 58.8 (6.7), respectively (p-value = 0.213). The models revealed no impact of the atherosclerosis risk level on the drugs' effects (p-values = 0.378, 0.975, 0.743 for IPSS, QMAX, and VOID, respectively). The present study's findings could not show the impact of atherosclerosis risk levels on the efficiency of Tamsolusin and Tadalafil in men with LUTS.Keywords
This publication has 19 references indexed in Scilit:
- Tadalafil: A Phosphodiesterase‐5 Inhibitor for Benign Prostatic HyperplasiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstructionBJU International, 2011
- Urodynamic Effects of Once Daily Tadalafil in Men With Lower Urinary Tract Symptoms Secondary to Clinical Benign Prostatic Hyperplasia: A Randomized, Placebo Controlled 12-Week Clinical TrialJournal of Urology, 2010
- Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentBJU International, 2010
- Prevalence and Characteristics of Lower Urinary Tract Symptoms in Men Aged ≥80 YearsUrology, 2008
- Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2007
- Impact of Lower Urinary Tract Symptoms on Quality of Life Using Functional Assessment Cancer Therapy ScaleUrology, 2007
- Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunctionBJU International, 2005
- Chronic Ischemia Increases Prostatic Smooth Muscle Contraction in the RabbitJournal of Urology, 2003
- Benign prostatic hyperplasiaThe Lancet, 2003